ARTICLE | Clinical News

Threshold down on Phase III data delay

September 23, 2014 3:09 AM UTC

Threshold Pharmaceuticals Inc. (NASDAQ:THLD) fell $0.50 (11%) to $3.97 on Monday after saying it expects delayed data from its Phase III trial of TH-302 to treat unresectable or metastatic soft tissue sarcoma (STS).

The delay is based on the results of a planned interim analysis of the 640-patient trial, which was conducted by an IDMC. ...